Search - IRCCS

MK-1026-003 (MSD)

Etude de phase 2 pour évaluer l’efficacité et l’innocuité du MK-1026 chez les participants atteints d’hémopathies malignes

See trial

Portrait de collaborateur du CHU Lyon Sud

Clinico-biological project manager

Clinico-biological project manager has a transversal and strategic role, combining scientific, logistical and administrative responsibilities, while being oriented towards results and innovation. His/her role leans on a wide range of skills, from scientific expertise to scientific expertise, operational logistics, and strategic communication.

Discover

Overcost project manager

The role of the overcost project manager is to negotiate clinical research contracts and additional costs for external projects (industrial and academic) in the lymphoid and myeloid sectors.

Discover

Administrative and financial manager

Administrative and financial manager supervises a portfolio of hematology-related associations, overseeing financial, accounting, tax, analytical, administrative and HR aspects.

Discover

88549968MPN1001 (JANSSEN)

Étude de première administration chez l’homme évaluant la sécurité, la pharmacocinétique et la pharmacodynamique du JNJ-88549968, un anticorps bispécifique de redirection des lymphocytes T dans le traitement des néoplasies myéloprolifératives NMP porteuses de mutations du gène CALR.

See trial

Accounting secretary

Accounting secretary is in charge of the administrative and accounting management of several associations linked to hematology.

Discover

75276617ALE1001_cAMeLot-1 (JANSSEN)

Étude de phase 1/2, première administration à l’homme de l’inhibiteur de Menin-KMT2A
(MLL1) Bleximenib chez des patients atteints de leucémie aiguë

See trial

DR-01-ONC-001 (DREN BIO)

A multicenter, open-label, first-in human (FIH), multiple expansion cohort, Phase 1/2 study to evaluate the safety and efficacy of DR-01 in adult subjects with large granular lymphocytic leukemia (LGLL) or cytotoxic lymphomas

See trial

DSP-5336-101 (SUMITOMO)

Étude de phase 1/2, ouverte, escalade et expansion de la dose de DSP-5336 chez des patients adultes atteints de leucémie aiguë avec ou sans réarrangement de la leucémie à lignées mixtes (MLL) ou mutation de la nucléophosmine 1 (NPM1)

See trial

Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial

Abramson JS, Ku M, Hertzberg M, Huang HQ, Fox CP, Zhang H, Yoon DH, Kim WS, Abdulhaq H, Townsend W, Herbaux C, Zaucha JM, Zhang QY, Chang H, Liu Y, Cheah CY, Ghesquieres H, Simko S, Orellana-Noia V, Ta R, Relf J, Dixon M, Kallemeijn M, Mulvihill E, Huang H, Lundberg L, Gregory GP

Accéder à l’article

Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial

Eunice S Wang, Ghayas C Issa, Harry P Erba, Jessica K Altman, Pau Montesinos, Stephane DeBotton, Roland B Walter, Kristen Pettit, Michael R Savona, Mithun Vinod Shah, Marina Kremyanskaya, Maria R Baer, James M Foran, Gary Schiller, Lionel Adès, Mael Heiblig, Celine Berthon, Pierre Peterlin, Eduardo Rodríguez-Arbolí, Olga Salamero, Mrinal M Patnaik, Cristina Papayannidis, Jolanta Grembecka, Tomasz Cierpicki, Bradley Clegg, Joshua Ray, Brian M Linhares, Kun Nie, Amitava Mitra, Julie Mackey Ahsan, Marilyn Tabachri, Harris S Soifer, Daniel Corum, Mollie Leoni, Stephen Dale, Amir T Fathi

Accéder à l’article

Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma

T M Kim, M Taszner, S Novelli, S-G Cho, J C Villasboas, M Merli, A Jiménez-Ubieto, B Tessoulin, L M Poon, D Tucker, J Walewski, S Yi, Y Song, G Chong, E Bachy, S Guidez, A Alonso, D Jagadeesh, W Zhang, L Magnano, E Iskierka-Jażdżewska, M Tani, B Shen, A Uppala, M Zhu, S Shariff, J Brouwer-Visser, A Chaudhry, H Mohamed, S Ambati, S Luminari; ELM-2 Investigators

Accéder à l’article